Asana Biosciences

30 articles about Asana Biosciences

• Asana BioSciences Announces Dosing of First Patient in Phase 1 Trial of ASN004, a Novel 5T4-Antibody-Drug-Conjugate

  4/8/2022

  Asana BioSciences, LLC, a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in a Phase 1 trial for ASN004, an antibody drug conjugate (ADC) targeting the 5T4 oncofetal antigen (trophoblast glycoprotein), that is expressed in a wide range of malignant tumors but shows very limited expression in normal tissues.

• Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Oral SYK/JAK Inhibitor Gusacitinib at AAD VMX Late-Breaking Session

  4/22/2021

  Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present additional positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) in adult patients with moderate-to-severe chronic hand eczema (CHE) in a late-breaking research program

• Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate-to-Severe Chronic Hand Eczema

  2/3/2021

  Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asana’s gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).

• Asana BioSciences to Present Clinical Data on Oral ASN007, A Novel ERK1/2 Inhibitor, at the 32nd EORTC-NCI-AACR Symposium

  10/22/2020

  Asana BioSciences, a clinical stage biopharmaceutical company, announced that ASN007 clinical data on safety, efficacy and pharmacokinetics in solid tumor patients will be presented at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics to be held on October 24-25, 2020.

• Asana BioSciences to Present Positive Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema in the Late-Breaking News Session at the EADV Virtual Congress

  10/20/2020

  Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) in adult patients with moderate-to-severe chronic hand eczema (CHE) in a late-breaking news session at the EADV Virtual Congress

• Asana BioSciences Announces Positive Topline Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib (ASN002) in Patients with Chronic Hand Eczema: Rapid and Significant Improvement Demonstrated

  6/2/2020

  Asana BioSciences announced today positive topline results from a Phase 2b study evaluating the efficacy and safety of its investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) in 97 adult patients with moderate-to-severe chronic hand eczema (CHE). The study was a randomized, double-blind, placebo-controlled, parallel-group study evaluating oral gusacitinib (40

• Asana BioSciences Announces Topical Sodium Channel Blocker ASN008 Achieves Positive Results for the Treatment of Pruritus in Atopic Dermatitis; Provides Update on JAK/SYK Inhibitor Gusacitinib in Phase 2 Studies for Chronic Hand Eczema and AD

  3/10/2020

  Asana BioSciences announced positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis for its topical sodium channel blocker, ASN008.

• Asana BioSciences to Present Phase 1 Clinical Safety and Efficacy Data of Oral, Once-Weekly, ASN007, a Novel ERK 1/2 Inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

  10/24/2019

  Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present ASN007 data on clinical safety and efficacy in solid tumor patients at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference to be held in Boston, MA on October 26-30, 2019.

• Asana BioSciences Strengthens Leadership Team as ASN002 Phase 2b RADIANT Trial in Atopic Dermatitis Advances with a Second Positive DSMB Recommendation

  2/26/2019

  Appointment of Shashank Mahashabde as VP of CMC and Pablo Jimenez, MD FAPCR as VP and Therapeutic Area Head of Immunology

• Asana BioSciences to Present Correlation Between Microbiome Changes and Clinical Efficacy With JAK/SYK Inhibitor ASN002 in the Late-Breaking News Session at the American Academy of Dermatology (AAD) Annual Congress

  2/18/2019

  First demonstration of changes in Staphylococcus aureus in lesional skin, correlating with clinical efficacy

• Asana BioSciences Announces Initiation of First-in-Human Clinical Study with ASN008, a Novel Topical Product for the Treatment of Pruritus Associated with Atopic Dermatitis

  12/20/2018

  ASN008 is a topical gel for the treatment of pruritus (itch) associated with atopic dermatitis.

• U.S. FDA Grants Fast Track Designation to Asana BioSciences’ Oral Dual JAK-SYK Inhibitor, ASN002, for the Treatment of Atopic Dermatitis

  12/10/2018

  Asana BioSciences is a clinical stage biopharmaceutical company

• Asana BioSciences to Present Late-Breaking Clinical and Biomarker Data for Its JAK/SYK Inhibitor ASN002 at the European Academy of Dermatology and Venereology (EADV) Annual Congress

  9/10/2018

  First demonstration of improvement in atopic dermatitis lesional skin phenotype towards uninvolved skin, correlating with clinical efficacy outcomes by an oral inhibitor of JAK-STAT signaling

• Asana BioSciences Initiates Phase 2b Study of ASN002 in Patients with Moderate-to-Severe Atopic Dermatitis (RADIANT)

  7/19/2018

  Asana Biosciences, a clinical stage biopharmaceutical company focused on discovery and development of novel targeted investigational medicines in Immunology/Inflammation and Oncology, today announced initiation of a Phase 2b study of ASN002, an oral JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis (AD).

• Asana BioSciences to Present Clinical Proof of Concept Study Results in Atopic Dermatitis with ASN002, A Novel Oral JAK/SYK Inhibitor, in the Late-Breaking Session at the American Association of Dermatology Annual Meeting

  1/31/2018

  Asana BioSciences today announced that it will present the clinical proof of concept study results with ASN002, an oral, once-daily dual JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis in the late-breaking session at the annual meeting of the American Association of Dermatology in San Diego to be held February 16 - 20, 2018.

• Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor

  1/3/2018

  Asana BioSciences announced that the U.S. FDA has accepted the IND application for ASN007, a potent and selective ERK1/2 inhibitor.

• Asana BioSciences to Present Updates on its Oncology Development Pipeline at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  10/24/2017

  Asana BioSciences announced that it will present updates regarding three of its lead molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Philadelphia, PA, October 26-30, 2017.

• Asana Biosciences Initiates Phase II Evaluation Of ASN002, A Novel Syk/Jak Inhibitor, In NHL, CLL And MF

  5/31/2017

• Asana Biosciences Highlights Progress In Its Oncology Portfolio With New Data At AACR 2017 On ASN002 (SYK/JAK Inhibitor), ASN003 (BRAF/PI3K Inhibitor) And ASN004 (5T4-Targeted Antibody Drug Conjugate)

  3/27/2017

• Asana Biosciences Announces FDA Acceptance Of The IND Application For Its Novel SYK-JAK Inhibitor For Evaluation In Atopic Dermatitis

  3/16/2017